vs
MESA LABORATORIES INC（MLAB）与Ralliant Corp（RAL）财务数据对比。点击上方公司名可切换其他公司
Ralliant Corp的季度营收约是MESA LABORATORIES INC的8.1倍（$529.1M vs $65.1M）。Ralliant Corp净利率更高（7.5% vs 5.6%，领先2.0%）。MESA LABORATORIES INC同比增速更快（3.6% vs -0.5%）。Ralliant Corp自由现金流更多（$126.6M vs $18.0M）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
MLAB vs RAL — 直观对比
营收规模更大
RAL
是对方的8.1倍
$65.1M
营收增速更快
MLAB
高出4.1%
-0.5%
净利率更高
RAL
高出2.0%
5.6%
自由现金流更多
RAL
多$108.6M
$18.0M
损益表 — Q3 2026 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $529.1M |
| 净利润 | $3.6M | $39.9M |
| 毛利率 | 64.2% | 50.8% |
| 营业利润率 | 12.2% | 9.8% |
| 净利率 | 5.6% | 7.5% |
| 营收同比 | 3.6% | -0.5% |
| 净利润同比 | 316.6% | -56.1% |
| 每股收益（稀释后） | $0.65 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRAL
| Q4 25 | $65.1M | — | ||
| Q3 25 | $60.7M | $529.1M | ||
| Q2 25 | $59.5M | $503.3M | ||
| Q1 25 | $62.1M | — | ||
| Q4 24 | $62.8M | — | ||
| Q3 24 | $57.8M | $531.7M | ||
| Q2 24 | $58.2M | $533.7M | ||
| Q1 24 | $58.9M | — |
净利润MLABRAL
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $39.9M | ||
| Q2 25 | $4.7M | $47.6M | ||
| Q1 25 | $-7.1M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | $90.9M | ||
| Q2 24 | $3.4M | $64.8M | ||
| Q1 24 | $-254.6M | — |
毛利率MLABRAL
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | 50.8% | ||
| Q2 25 | 62.0% | 49.3% | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | 52.6% | ||
| Q2 24 | 64.0% | 51.5% | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRAL
| Q4 25 | 12.2% | — | ||
| Q3 25 | 7.8% | 9.8% | ||
| Q2 25 | 5.1% | 11.7% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 6.1% | 20.9% | ||
| Q2 24 | 9.6% | 19.7% | ||
| Q1 24 | -460.6% | — |
净利率MLABRAL
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | 7.5% | ||
| Q2 25 | 8.0% | 9.5% | ||
| Q1 25 | -11.4% | — | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | 17.1% | ||
| Q2 24 | 5.8% | 12.1% | ||
| Q1 24 | -432.2% | — |
每股收益（稀释后）MLABRAL
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | $0.35 | ||
| Q2 25 | $0.85 | $0.42 | ||
| Q1 25 | $-1.30 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | $0.81 | ||
| Q2 24 | $0.62 | $0.57 | ||
| Q1 24 | $-47.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $264.2M |
| 总债务越低越好 | $68.4M | $1.1B |
| 股东权益账面价值 | $186.7M | $3.0B |
| 总资产 | $434.8M | $5.3B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.39× |
8季度趋势，按日历期对齐
现金及短期投资MLABRAL
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | $264.2M | ||
| Q2 25 | $21.3M | $198.6M | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
总债务MLABRAL
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | $1.1B | ||
| Q2 25 | $70.3M | $1.1B | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRAL
| Q4 25 | $186.7M | — | ||
| Q3 25 | $178.5M | $3.0B | ||
| Q2 25 | $172.5M | $3.0B | ||
| Q1 25 | $159.8M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $161.5M | $4.0B | ||
| Q2 24 | $150.7M | $4.0B | ||
| Q1 24 | $145.4M | — |
总资产MLABRAL
| Q4 25 | $434.8M | — | ||
| Q3 25 | $430.4M | $5.3B | ||
| Q2 25 | $435.7M | $5.2B | ||
| Q1 25 | $433.3M | — | ||
| Q4 24 | $433.3M | — | ||
| Q3 24 | $454.1M | — | ||
| Q2 24 | $440.4M | — | ||
| Q1 24 | $446.8M | — |
负债/权益比MLABRAL
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | 0.39× | ||
| Q2 25 | 0.41× | 0.38× | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $138.6M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $126.6M |
| 自由现金流率自由现金流/营收 | 27.7% | 23.9% |
| 资本支出强度资本支出/营收 | 1.1% | 2.3% |
| 现金转化率经营现金流/净利润 | 5.17× | 3.47× |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABRAL
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.2M | $138.6M | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $12.7M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $12.9M | — |
自由现金流MLABRAL
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | $126.6M | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
自由现金流率MLABRAL
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | 23.9% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
资本支出强度MLABRAL
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | 2.3% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
现金转化率MLABRAL
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 3.47× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
